Latest headlines
GSK plc News
The latest GSK plc (GSK) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these GSK headlines next to the live GSK plc Fear and Greed Index.
Latest GSK plc Headlines59
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
reuters.com · Jul 30, 2026
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
zacks.com · Jul 29, 2026
GSK plc (GSK) Q2 2026 Earnings Call Transcript
seekingalpha.com · Jul 28, 2026
GSK Q2 Earnings Call Highlights
marketbeat.com · Jul 28, 2026
GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)
seekingalpha.com · Jul 28, 2026
GSK hits three-month high as vaccines help earnings top forecasts
proactiveinvestors.com · Jul 28, 2026
GSK hits three-month high as vaccines help earnings top forecasts
proactiveinvestors.co.uk · Jul 28, 2026
GSK (GSK) Beats Q2 Earnings and Revenue Estimates
zacks.com · Jul 28, 2026
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
wsj.com · Jul 28, 2026
GSK beats second-quarter profit estimates, launches $2.52 billion cost savings drive
reuters.com · Jul 28, 2026
GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts
reuters.com · Jul 28, 2026
GSK, Hansoh's cancer drug meets main goal of bone cancer trial
reuters.com · Jul 28, 2026
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
invezz.com · Jul 24, 2026
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
zacks.com · Jul 23, 2026
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
zacks.com · Jul 23, 2026
Will GSK's Specialty Medicines Boost Q2 Revenue Growth?
zacks.com · Jul 23, 2026
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
prnewswire.com · Jul 22, 2026
US FDA approves GSK's lung cancer drug
reuters.com · Jul 22, 2026
GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com · Jul 21, 2026
GSK: Buy The Discount Before The Catalysts Close It
seekingalpha.com · Jul 21, 2026
AI Bubble Risks Make Dividend Stocks Attractive Again
seekingalpha.com · Jul 18, 2026
GSK Discontinues Development of Camlipixant for Refractory Chronic Cough
zacks.com · Jul 17, 2026
Disappointing Data Prompts GSK to Drop Cough Drug Development
benzinga.com · Jul 17, 2026
Jefferies resumes GSK coverage at 'buy', sees 30% upside on oncology firepower
proactiveinvestors.co.uk · Jul 17, 2026
GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
wsj.com · Jul 17, 2026
GSK to halt further development of cough drug after missing main goal
reuters.com · Jul 17, 2026
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
zacks.com · Jul 14, 2026
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
gurufocus.com · Jul 13, 2026
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
businesswire.com · Jul 13, 2026
UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
proactiveinvestors.com · Jul 13, 2026
UBS keeps GSK at 'neutral' with focus on chief executive's strategy update
proactiveinvestors.co.uk · Jul 13, 2026
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
reuters.com · Jul 13, 2026
GSK's targeted cancer therapy shows positive results in late-stage study
reuters.com · Jul 10, 2026
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
reuters.com · Jul 8, 2026
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
reuters.com · Jul 8, 2026
Is GSK Quietly Becoming An Oncology Powerhouse
seekingalpha.com · Jun 25, 2026
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
seekingalpha.com · Jun 18, 2026
Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout
zacks.com · Jun 18, 2026
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
zacks.com · Jun 18, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
businesswire.com · Jun 17, 2026
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
globenewswire.com · Jun 17, 2026
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
reuters.com · Jun 17, 2026
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
zacks.com · Jun 16, 2026
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
zacks.com · Jun 12, 2026
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
gurufocus.com · Jun 11, 2026
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
zacks.com · Jun 11, 2026
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
marketbeat.com · Jun 11, 2026
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
reuters.com · Jun 11, 2026
GSK plc (GSK) M&A Call Transcript
seekingalpha.com · Jun 10, 2026
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
businesswire.com · Jun 10, 2026
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
proactiveinvestors.co.uk · Jun 10, 2026
Thistle Resources intersects broad gold mineralization at Middle River
proactiveinvestors.com · Jun 10, 2026
Snail Games brings Bellwright to PlayStation and Xbox as console push advances
proactiveinvestors.com · Jun 10, 2026
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
proactiveinvestors.com · Jun 10, 2026
Abacus Global Management launches AI lifespan modeling platform
proactiveinvestors.com · Jun 10, 2026
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
wsj.com · Jun 9, 2026
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
zacks.com · Jun 9, 2026
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
zacks.com · Jun 9, 2026
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline
gurufocus.com · Jun 9, 2026
Why Is GSK plc Up or Down Today?
When GSK plc (GSK) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a GSK move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why GSK plc is up or down today.
How GSK plc News Affects the Price
News does not move the GSK plc (GSK) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the GSK plc Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in GSK plc trading volume. That is the chain to watch: headline, sentiment, volume, then the GSK price.
Trade the GSK plc News With Sentiment
Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch GSK plc trading volume spike on a big story, check the GSK plc price history for context, follow the live GSK price, see the GSK plc price prediction, and read the GSK plc Fear and Greed Index for mood.
How do you feel about GSK plc?
1DFrequently asked questions
Why is GSK plc up or down today?
What is the latest GSK plc news?
Where does GSK plc news come from?
How often is GSK plc news updated?
How does GSK plc news relate to its Fear and Greed Index?
Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.
About CFGI
The per-asset sentiment record.
CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.
Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.